Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
Authors Kim DH, Jeong YI, Chung CW, Kim CH, Kwak TW, Lee HM, Kang DH
Received 31 January 2013
Accepted for publication 18 March 2013
Published 30 April 2013 Volume 2013:8(1) Pages 1697—1711
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Do Hyung Kim,1,2,* Young-Il Jeong,1,* Chung-Wook Chung,1 Cy Hyun Kim,1,2 Tae Won Kwak,1 Hye Myeong Lee,1 Dae Hwan Kang1,2
1National Research and Development Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, 2School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do, South Korea
*These authors equally contributed to this work.
Background: Cholangiocarcinoma is a malignant tumor arising from the epithelium of the bile ducts. In this study, we prepared sorafenib-loaded biliary stents for potential application as drug-delivery systems for localized treatment of extrahepatic cholangiocarcinoma.
Methods: A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ε-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo. Anticancer activity of sorafenib against HuCC-T1 cells was evaluated by the proliferation test, matrix metalloproteinase (MMP) activity, cancer cell invasion, and angiogenesis assay in vitro and in vivo.
Results: The drug-release study showed that the increased drug content on the PCL film induced a faster drug-release rate. The growth of cancer cells on the sorafenib-loaded PCL film surfaces decreased in a dose-dependent manner. MMP-2 expression of HuCC-T1 cells gradually decreased according to sorafenib concentration. Furthermore, cancer cell invasion and tube formation of human umbilical vein endothelial cells significantly decreased at sorafenib concentrations higher than 10 mM. In the mouse tumor xenograft model with HuCC-T1 cells, sorafenib-eluting PCL films significantly inhibited the growth of tumor mass and induced apoptosis of tumor cells. Various molecular signals, such as B-cell lymphoma (Bcl)-2, Bcl-2-associated death promoter, Bcl-x, caspase-3, cleaved caspase-3, Fas, signal transducer and activator of transcription 5, extracellular signal-regulated kinases, MMP-9 and pan-janus kinase/stress-activated protein kinase 1, indicated that apoptosis, inhibition of growth and invasion was cleared on sorafenib-eluting PCL films.
Conclusion: These sorafenib-loaded PCL films are effective in inhibiting angiogenesis, proliferation and invasion of cancer cells. We suggest that sorafenib-loaded PCL film is a promising candidate for the local treatment of cholangiocarcinoma.
Keywords: sorafenib, polycaprolactone, biliary stent, human cholangiocarcinoma cells, angiogenesis
A Letter the the Editor has been received and published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice
Zhu PL, Pan SY, Zhou SF, Zhang Y, Wang XY, Sun N, Chu ZS, Yu ZL, Ko KM
Published Date: 17 February 2015
Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I
Published Date: 23 October 2013
Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-α and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line
Wang YC, Mo L, Wei WB, Shi XH
Published Date: 2 October 2013
Yue PF, Li Y, Wan J, Wang Y, Yang M, Zhu WF, Wang CH, Yuan HL
Published Date: 9 August 2013
FarrokhTakin E, Ciofani G, Puleo GL, de Vito G, Filippeschi C, Mazzolai B, Piazza V, Mattoli V
Published Date: 28 June 2013
Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung
Numata M, Grinkova YV, Mitchell JR, Chu HW, Sligar SG, Voelker DR
Published Date: 15 April 2013
Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138– CD34– tumor stem-like cells in multiple myeloma-bearing mice
Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J
Published Date: 12 April 2013
Zhang JX, Wang K, Mao ZF, Fan X, Jiang DL, Chen M, Cui L, Sun K, Dang SC
Published Date: 8 April 2013
Degradation and osteogenic potential of a novel poly(lactic acid)/nano-sized β-tricalcium phosphate scaffold
Cao L, Duan PG, Wang HR, Li XL, Yuan FL, Fan ZY, Li SM, Dong J
Published Date: 28 November 2012
Wang S, Inci F, Chaunzwa TL, Ramanujam A, Vasudevan A, Subramanian S, Ip AC, Sridharan B, Gurkan UA, Demirci U
Published Date: 29 May 2012